15 citations
,
March 2024 in “Journal of Clinical Medicine” In this four-year study, pediatric patients with inoperable plexiform neurofibromas and type 1 neurofibromatosis treated with selumetinib frequently experienced dermatologic side effects, which required tailored management strategies and sometimes led to treatment suspension, potentially affecting tumor regrowth.
12 citations
,
August 1988 in “Histopathology” This case report describes a giant pigmented tumor of the scalp in a 47-year-old woman and suggests a possible dual origin involving neural crest differentiation.
November 2022 in “Journal of Investigative Dermatology” This study identified a novel LZTR1 mutation associated with hybrid schwannoma and neurofibroma in a patient with schwannomatosis, but not all cases of hybrid tumors are linked to this condition.
August 2025 in “Ophthalmic Plastic and Reconstructive Surgery” In this case report, a 4-year-old with neurofibromatosis type 1 experienced significant reduction in an inoperable periorbital plexiform neurofibroma and visual improvement following treatment with selumetinib.
September 2024 in “Egyptian Journal of Medical Human Genetics” This case report adds to the understanding of neurofibromatosis type 1 by documenting an Egyptian child with the condition alongside multiple unusual congenital anomalies, highlighting the importance of considering NF1 when these features are present.